Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration

Purpose. To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration. Methods. This retrospective st...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffin, David R., Richmond, Preston P., Olson, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258314/
https://www.ncbi.nlm.nih.gov/pubmed/25505976
http://dx.doi.org/10.1155/2014/497178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258314/
https://www.ncbi.nlm.nih.gov/pubmed/25505976
http://dx.doi.org/10.1155/2014/497178

Ejemplares similares